PROM1 and neoplasm: In 2004, Singh and colleagues11 identified CD133 as a CSC marker in brain TICs because injection of as few as 100 CD133+ cells produced a tumor that could be serially transplanted and was a phenocopy of the patient’s original tumor, whereas injection of 105 CD133− cells engrafted but did not result in a tumor.